TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $90

Benzinga · 3d ago
TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $79 to $90.